Skip to main content

Advertisement

Table 4 Relationship between persistency index and outcome measures (mixed effects regression analysis)

From: Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

  Beta coefficientb (standard error)
Outcome(s) with adjustmenta Intercept Time, years Persistency index Persistency index × time
MMSE 3.89 (2.001) -2.58 (0.13)c -1.09 (0.77) 1.02 (0.23)c
ADAS-Cogd 55.45 (5.65)c 3.68 (0.66)c -3.75 (2.09) 2.74 (1.32)e
BPMSE 10.46 (3.47)e -2.55 (0.25)c -1.76 (1.90) 1.00 (0.52)
PSMS 10.03 (1.85)c 1.68 (0.12)c -0.09 (0.66) -0.43 (0.21)f
IADL 18.63 (2.54)c 2.36 (0.17)c 4.19 (0.91)c -1.42 (0.29)c
CDR-SB 11.43 (1.43)c 1.67 (0.09)c 1.42 (0.54)e -0.61 (0.17)g
  1. aAdjustment made for early exposure index, gender, education, age, pre-progression rate, and the severity of disease at baseline. bMean change in score associated with each variable. cP < 0.0001. dWhen the linear trend and quadratic trend change were included in the model the coefficients (standard errors) for time-squared and time-squared by persistency index interaction are 0.19 (0.14) and -0.83 (0.26)e, respectively. eP < 0.01; fP < 0.05; gP < 0.001; otherwise, P = not significant, based on type 3 F test. ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive Subscale; BPMSE, Baylor Profound Mental Status Examination; CDR-SB, Clinical Dementia Rating-Sum of Boxes; IADL, Instrumental Activities of Daily Living; MMSE, Mini-Mental State Examination; PSMS, Physical Self-Maintenance Scale.